Leuprorelin
Top View
- Firmagon, INN-Degarelix
- A New Sustained-Release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients with Prostate Cancer
- Leuprorelin- Containing Depot Medicinal Products
- Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer
- Degarelix DTC Summary
- The Role of Gonadotropin-Releasing Hormone (Gnrh) in Endometrial Cancer
- A Case Report of 10 Finnish Patients with Advanced Prostate Cancer
- Summary of Product Characteristics
- Role of Gonadotropin-Releasing Hormone (Gnrh) in Ovarian Cancer
- Leuprorelin (Prostap®) for the Treatment of Prostate Cancer
- Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer
- Medical Management of Gender Transition
- Leuprorelin Acetate (N=142)
- Gonadotropin-Releasing Hormone (Gnrh) Analogues in Prostate Cancer
- Gonadorelin Analogues for Endometriosis
- Australian Public Assessment Report for Leuprorelin Acetate
- Elagolix for Endometriosis
- New Zealand Consumer Medicine Information